| Name | Description | Data sources | Responsible organisation(s) | Measure methodology last updated |
|---|---|---|---|---|
| People with diabetes aged 25 years or over regularly receiving an ACEI or ARB in the relevant year | This indicator shows the number and percent of people with diabetes receiving angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) in three or four quarters in the relevant year |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| Proportion of medical-surgical bed-days for people with diabetes | This indicator shows the number and proportion of medical-surgical bed-days in people with any diagnosis of diabetes compared to total medical-surgical bed-days. |
National Minimum Dataset (NMDS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People regularly dispensed a short-acting beta agonist (SABA) who were not dispensed preventer during the year | People aged 5–44 regularly dispensed a short-acting beta agonist (SABA) who were not dispensed preventer anytime during the year, among PHO enrolled population. This indicator shows the number and percent of people who were dispensed SABA in at least two quarters in a year and not dispensed preventer in the same year. |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection | Health Quality & Safety Commission | Te Tāhū Hauora | September 2025 |
| People not dispensed ICS regularly in the year after admission | This indicator shows the number and percent of people aged 5 –44 years who were not regularly dispensed ICS in the four quarters after discharge for an admission with a primary diagnosis of asthma. Regular dispensing was defined as dispensing in two or more quarters in the year post discharge. This was calculated using the date of discharge and dividing the following 365 days into four quarters. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection | Health Quality & Safety Commission | Te Tāhū Hauora | September 2025 |
| PHO enrolled population not given a funded influenza vaccine in the year after admission | People admitted in the previous year with a primary diagnosis of asthma (or wheeze for children; see denominator for codes) who did not receive a funded influenza vaccine in the year following discharge. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS) | Health Quality & Safety Commission | Te Tāhū Hauora | September 2025 |
| Children admitted to hospital one or more times with a primary diagnosis of asthma or wheeze | This measure gives the rate of children under 12 years who were admitted to hospital with asthma and wheeze as the primary diagnosis per 1,000 children. |
National Minimum Dataset (NMDS), PHO Enrolment Collection | Health Quality & Safety Commission | Te Tāhū Hauora | September 2025 |
| People dispensed an antibiotic specifically indicated for urinary tract infections, rate per 100 | This measure details the rate per 100 of people dispensed an antibiotic specifically indicated for urinary tract infections (UTIs). Nitrofurantoin or trimethoprim are recommended as first-line treatment for UTIs. Norfloxacin is second-line treatment. The rationale for this measure is to explore the use of antibiotics for UTIs, with a view to identifying whether there are areas of high use of these antibiotics. | Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Ministry of Health | Health Quality & Safety Commission | Te Tāhū Hauora | |
| People in ARC dispensed an antibiotic specifically indicated for UTIs, rate per 100 | This measure details the rate per 100 of people listed in ARC dispensed an antibiotic specifically indicated for urinary tract infections (UTIs). Nitrofurantoin or trimethoprim are recommended as first-line treatment for UTIs. Norfloxacin is second-line treatment. The rationale for this measure is to explore the use of antibiotics for UTIs, with a view identifying whether there are areas of high use of these antibiotics. | Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Ministry of Health | Health Quality & Safety Commission | Te Tāhū Hauora | |
| People with at least two hospital admissions within 90 days of each other with a primary diagnosis of asthma (or wheeze in children) | This indicator shows the number and percent of people with at least two admissions within 90 days of each other. ED admissions meeting the three-hour rule are included in this indicator. |
National Minimum Dataset (NMDS), PHO Enrolment Collection | Health Quality & Safety Commission | Te Tāhū Hauora | September 2025 |
| People with at least two admissions within 91–365 days of each other with a primary diagnosis of asthma (or wheeze in children) | This indicator shows the number and percent of people aged zero (more than 28 days old) year of age or over who had at least two admissions with a primary diagnosis of asthma within 91 to 365 days of each other. The method counts back the number of days between the admit date of the most recent admission and the date of discharge of the previous event. ED admissions meeting the three-hour rule are included in this indicator. |
National Minimum Dataset (NMDS), Primary Health Organisation (PHO) Enrolment Collection | Health Quality & Safety Commission | Te Tāhū Hauora | September 2025 |